Skip to the content

Let Tomorrow Begin Today

Innovation in Cell Therapy at MSK

The Stem Cell Transplantation Service at Memorial Sloan Kettering Cancer Center (MSK) was one of the first in the United States and has grown to become one of the largest. More than 2,500 allogeneic and 2,500 autologous bone marrow or peripheral blood stem cell transplants have been performed at this Center. Our founding physicians were pioneers in the field, completing the first transplant using bone marrow from an unrelated donor in 1974. 

MSK Scientists are also pioneers in the CAR T Cell immunotherapy breakthrough. Groundbreaking MSK studies led by Michel Sadelain, Director of MSK’s Center of Cell Engineering, and Renier Brentjens, Director of MSK’s Cellular Therapeutics, revolutionized the treatment landscape for patients with therapy-refractory lymphoma and leukemia who have received these genetically modified T cells. We are also world-renowned for innovation in:

· Optimizing outcomes for transplantation as curative option for a variety of (mainly pediatric) non-malignant indications: e.g. primary immune deficiencies, bone marrow failure syndromes, heamoglobinopathies, inherited metabolic diseases
· The introduction of T cell depletion as a way to prevent graft-versus-host disease (GVHD) in 1979 using soybean agglutination and E-rosetting and now with CD34 Selection. CD34 selection is now used in a number of centers worldwide and is being compared to other alternative strategies of GVHD prevention.
· The introduction of a new total body irradiation regimen - this hyperfractionated method was developed as part of the myeloablative conditioning of patients with leukemia or lymphoma to increase the antitumor effect and decrease the short and long-term side effects of radiation. Marrow transplantation using this regimen has resulted in low posttransplant relapse rates and has also reduced the long-term effects of radiation on growth and other endocrine function
· The implementation of novel gut microbiota research findings in the clinical setting – recent research at this Center highlights associations between bone marrow transplantation and the bacteria that naturally reside in the gut. These findings have led to clinical trials aimed at managing complications of transplant such as graft-versus-host disease (GVHD) and infection.
· Providing varied options for patients to receive care in the outpatient setting
· Personalizing the chemotherapy given prior to transplant to reduce toxicity and to improve survival chances
· Reviewing treatment of hematological malignancies during the dawn of the era of immunotherapies in the form of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells.

TCT Meetings Speakers

Sneha Purvey 23 Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/Dl Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response (RR) at 1 Year in Light Chain (AL) Amyloidosis 2:45 - 3:00pm
World Center Marriott - Palms: Royal
Alex Gomez-Arteaga 25:  Time to Relapse and the Patterns of Relapse Are Prognostic for Post-Relapse Survival after CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma 3:15pm - 3:30pm
World Center Marriott - Palms: Royal
Ann Jakubowski Survivorship Visits Post-Transplant – Essentials & Ideals 12:55 - 1:15pm
World Center Marriott - Palms: Canary 3
Kevin Curran 120 Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies 3:45 - 4:00pm
World Center Marriott - Grand: Salon 14
Martina Pennisi  51 Comparing Car T Cells Toxicities Grading Systems: Application of Astct Grading System and Implications for Management 5:45 - 6:00pm
World Center Marriott - Cypress 3
Boglarka Gyurkocza 39 Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial 4:45 - 5:00pm
World Center Marriott - Palms: Sabal
Ioannis Politikos  36 Addition of Tocilizumab to Cyclosporine-a/ Mycophenolate Mofetil (CSA/ MMF) Graft-Vs-Host Disease (GVHD) Prophylaxis Significantly Abrogates Pre-Engraftment Syndrome (PES) & Severe Acute Gvhd after Adult Double Unit Cord Blood Transplantation (dCBT) 6:00 - 6:15pm
World Center Marriott - Palms: Royal
Richard O'Reilly 46 Outcomes of Two Chemotherapy-Based Preparatory Regimens Compared to TBI-Based Conditioning When Used with CD34+ Selected T-Cell Depleted Allohct for High Risk Hematologic Malignancies: Prospective Clinical Trial NCT 01119066 6:30 - 6:45pm
World Center Marriott - Palms: Sabal
Miguel Perales The Importance of Interoperability for HCT and CT Data 6:30 - 6:45pm
World Center Marriott - Palms: Canary 1-2
Gunjan Shah 56 Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

10:45 - 11:00am
World Center Marriott - Palms: Sabal

Doris Ponce 68 A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract 10:45 - 11:00am
World Center Marriott - Cypress 3
Sergio Giralt A Look at the Diagnostic Challenges in TA-TMA

7:00 - 7:15am

World Center Marriott - Cypress 3

Juliet Barker Multi-Center Trial Proposals: Adults

4:00 - 4:15pm

World Center Marriott - Crystal: H                                                               

Richard Lin 85 Burden and Impact of Geriatric Syndromes in 2-Year, Progression-Free Survivors of Older Allogeneic Hematopoietic Cell Transplant Recipients – a Landmark Analysis

10:30 - 10:45 am

World Center Marriott - Palms: Royal

Exciting New Facility

The David H. Koch Center for Cancer Care opened to patients in January 2020 and provides a dynamic setting for leading-edge cancer treatment. The David H. Koch Center re-designs the way in which cancer care is provided, with an emphasis on innovation,  continuous data-driven improvement, and optimized patient experience. Our team is always seeking exceptional Faculty, Advanced Practice Providers, PharmD, Data Managers and more to join us and make a difference every day.

Visit us during the TCT Meetings to learn more. 

Upcoming Events at MSK

Click on the links below for more information and to register for upcoming events. 

8th Annual Hematology and Medical Oncology Board Review: Contemporary Practice

Date03/19/2020
LocationNew York City

Memorial Sloan Kettering Cancer Alliance: 2nd Annual Advanced Practice Provider Oncology Symposium

Date03/21/2020
LocationZuckerman Research Center, New York, NY
Back to top